ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Annexin A13 Protects Against Acute Kidney Injury by Inactivating TGF-β/Smad3 Signaling.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transition from acute kidney injury to chronic kidney disease: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
- Single-cell Stereo-seq reveals regulatory mechanisms driving regeneration of injured proximal tubules during AKI.Nature communications · 2026Article
- Annexin A13 Protects Against Acute Kidney Injury by Inactivating TGF-β/Smad3 Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Acute kidney injury (AKI) is a common cause of chronic kidney disease, but the underlying pathogenesis remains unclear, and treatment options are limited. Here we report that Annexin A13 (ANXA13), the founder member of Annexins, is renoprotective in AKI. Clinically, ANXA13 is lost in the kidneys of patients with AKI and in mice with ischemic-reperfusion injury (IRI)- or cisplatin-induced AKI. This was associated with reduced serum ANXA13 and elevated urinary ANXA13 levels in the patients. Functionally, ANXA13 overexpression protected against IRI- and cisplatin-induced AKI, whereas ANXA13 silencing promoted AKI. This was further confirmed in renal tubule epithelial cell-specific Anxa13 knockout mice, in which deletion of tubular Anxa13 significantly exacerbated IRI- and cisplatin-induced AKI. Mechanistically, ANXA13 directly binds to the TGF-β receptor type 1 intracellular domain and inhibits its phosphorylation. This inactivates Smad3 signaling and blocks Smad3-mediated tubular cell death via p21-dependent G1 cell cycle arrest. Furthermore, our findings revealed that ANXA13 was negatively regulated by TGF-β/Smad3 signaling, as Smad3 could bind to the 3'UTR of ANXA13 and inhibit its transcription, which was confirmed in Smad3 Knockout mice. In conclusion, ANXA13 is renoprotective in AKI and may be a novel therapeutic agent for AKI by targeting TGF-β/Smad3 signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.